Ansprechpartner

Dr. med. Franz Xaver Breu
E-Mail

Dr. med. Stephan Guggenbichler
E-Mail

Prof. Dr. med. Bigit Kahle
E-Mail

Dr. med. Renate Murena
E-Mail

Vorstand

Dr. med. Franz Xaver Breu

Dr. Univ. Parma Stephan Guggenbichler

Prof. Dr. med. Birgit Kahle

Dr. med. Renate Murena-Schmidt

Themen

  • Durchführung von Umfragen, experimentellen und klinischen Studien sowie von Anwendungsbeobachtungen
  • Etablierung eines (inter-) nationalen Expertennetzwerkes zum Thema Sklerotherapie
  • Durchführung von Hands-on Kursen zur Sklerotherapie
  • Ansprechpartner für Krankenkassen, KVen und weitere Gesundheitsdienstleister zum Thema Sklerotherapie sowie Interessensvertreter der Ärzte bei diesen Institutionen

Ziele

Ziel der Arbeitsgemeinschaft ist es, die Sklerosierungstherapie als Therapieoption neben den anderen varizenausschaltenden Maßnahmen darzustellen und zu etablieren.

Tätigkeiten

Alle unsere Aktivitäten sind ausgerichtet auf die Etablierung der Sklerosierungstherapie als Therapieoption neben den anderen varizenausschaltenden Maßnahmen. Daher fördern und koordinieren wir wissenschaftliche Kooperationen im Kontext der Sklerosierungstherapie, stellen eine Plattform für wissenschaftliche Studien und Umfragen dar, bauen ein Expertennetzwerk auf und bieten Seminare, Hospitationen und Fortbildungen. Für unsere AG-Mitglieder stellen wir Aufklärungsbögen für Patienten sowie Abrechnungsempfehlungen zur Verfügung. Um diese zu erhalten können Sie sich hier einloggen. 

Insbesondere der medizinische Nachwuchs wird in unserer Arbeitsgemeinschaft gezielt unterstützt. Bei Interesse an unseren Angeboten für den medizinischen Nachwuchs wenden Sie sich bitte an: Dr. med. Franz Xaver Breu. In Zusammenarbeit mit der AG Sklerotherapie finden regelmäßig zahlreiche Hands-on-Kurse zum Erlernen der Sklerosierungstherapie statt. Die Weiterbildungsinhalte dieser Seminare werden kontinuierlich den aktuellen Entwicklungen in der Phlebologie angepasst und weiterentwickelt. Sie werden auch für das Fortbildungszertifikat der Deutschen Gesellschaft für Phlebologie anerkannt.

Hier kommen Sie zu den Terminen. 

Ein aktiver Austausch zwischen den AG-Mitgliedern ist unser Ziel, daher stellen wir Ihnen innerhalb des Mitgliedsbereichs, die Kontakte sämtlicher AG-Mitglieder im Downloadbereich der AG Sklerosierungstherapie zur Verfügung. Hier geht es zum Log In.

Veröffentlichungen

Hier finden Sie eine Übersicht der Top 10 der jährlichen Veröffentlichungen.

2013

2013

  • Rabe E; Breu F X; Cavezzi A; Coleridge Smith P; Frullini A; ; Gillet J L; Guex J J; Hamel-Desnos C; Kern P; Partsch B; Ramelet A A; Tessari L; Pannier F:
    European guidelines for sclerotherapy in chronic venous disorders.
    Phlebology, Epub ahead of print, 2013

  • Gillet J-L:
    Foam sclerotherapy of saphenous veins-Results and side effects.
    Rev vasc med 1, 1, 24-29, 2013

  • Schuller-Petrovic S; Pavlovic M D; Schuller S; Schuller-Lukic B; Adamic M:
    Telangiectasias resistant to sclerotherapy are commonly connected to a perforating vessel.
    Phlebology 28, 6, 320-323, 2013

  • Willenberg T; Smith P C; Shepherd A; Davies A H:
    Visual disturbance following sclerotherapy for varicose veins, reticular veins and telangiectasias: a systematic review.
    Phlebology 28, 3, 123-131, 2013

  • Reich-Schupke S; Doerler M; Altmeyer P; Stücker M:
    Foam sclerotherapy with Enoxaparin prophylaxis in high-risk patients with postthrombotic syndrome.
    VASA 42, 1, 50-55, 2013

  • Shadid N H; Van Der Velden S K; Van Oerle R; Ten Cate H; Sommer A; Nelemans P:
    In vivo effects of Foam Sclerotherapy on coagulation.
    Phlebology, Epub ahead of print. 2013

  • Rathbun S; Norris A; Morrison N; Gibson K; Raymond-Martimbeau P; Worthington-Kirsch R; Hohenwalter E; Lohr J; McLafferty R; Stoner J:
    Performance of endovenous foam sclerotherapy in the USA for the treatment of venous disorders:
    ACP/SVM/AVF/SIR quality improvement guidelines, Phlebology, Epub ahead of print, 2013

  • Cameron E; Chen T; Connor D E; Behnia M; Parsi K:
    Sclerosant foam structure and stability is strongly influenced by liquid air fraction.
    European Journal of Vascular and Endovascular Surgery 46, 4, 488-494, 2013

  • Van Eekeren R R J P; Boersma D; Konijn V; de Vries J P P M; Reijnen M M J P:
    Postoperative pain and early quality of life after radiofrequency ablation and mechanochemical endovenous ablation of incompetent great saphenous veins.
    J Vasc Surg 57, 2, 445-450, 2013

  • Williamsson C; Danielson P; Smith L:
    Catheter-directed foam sclerotherapy for chronic venous leg ulcers.
    Phlebology Epub ahead of print, 2013
2014

2014

  • Bishawi M; Bernstein R; Boter M; Draughn D; Gould C F; Hamilton C; Koziarski J:
    Mechanochemical ablation in patients with chronic venous disease: A prospective multicenter report
    Phlebology | 29, 6, 397-400 | 2014

  • Carroll C; Hummel S; Leaviss J; Ren S; Stevens JW; Cantrell A; Michaels J:
    Systematic review, network meta-analysis and exploratory cost-effectiveness model of randomized trials of minimally invasive techniques versus surgery for varicose veins
    Br J Surg | 101, 9, 1040-1052 | 2014

  • Devereux N; Recke A L; Westermann L; Recke A; Kahle B
    Catheter-directed Foam Sclerotherapy of Great Saphenous Veins in combination with Pre-Treatment Reduction of the diameter employing the principals of perivenous tumescent local anesthesia
    Eur J Vasc Endovasc Surg | 47, 2, 187-195 | 2014

  • Gillet J L; Lausecker M; Sica M; Guedes J M; Allaert F A:
    Is the treatment of the small saphenous veins with foam sclerotherapy at risk of deep vein thrombosis?
    Phlebology | 29, 9, 600-607 | 2014

  • Kiguchi M M; Hager E S; Winger D G; Hirsch S A; Chaer R A; Dillavou E D:
    Factors that influence perforator thrombosis and predict healing with perforator sclerotherapy for venous ulceration without axial reflux
    J Vasc Surg | 59, 5, 1368-1376 | 2014

  • Myers K A; Clough A M:
    Ultrasound-guided sclerotherapy using liquid sclerosant after preliminary saline flush
    Veins and Lymph | 3, 1, 11-14 | 2014

  • Perrin M:
    Randomized control trials on sclerotherapy for varicose veins
    Phlebolymphology | 21, 2, 81-94 | 2014

  • Rathbun S; Norris A; Morrison N; Gibson K; Raymond-Martimbeau P; Worthington-Kirsch R; Hohenwalter E; Lohr J; McLafferty R; Stoner J:
    Performance of endovenous foam sclerotherapy in the USA for the treatment of venous disorders: ACP/SVM/AVF/SIR quality improvement guidelines
    Phlebology | 29, 2, 76-82 | 2014

  • Reich-Schupke S:
    Sklerotherapie - Tipps und Tricks für den praktischen Alltag
    Vasomed | 26, 6, 138-145 | 2014

  • Shadid N H; Van Der Velden S K; Van Oerle R; Ten Cate H; Sommer A; Nelemans P:
    In vivo effects of Foam Sclerotherapy on coagulation
    Phlebology | 29, 5, 287-292 | 2014

  • Sommer A:
    Schaumsklerosierung: Positionierung im Bereich der nicht-thermischen Ablationsverfahren
    Phlebologie Germany | 43, 5, 239-241 | 2014
2015

2015

  • Siribumrungwong B, Noorit P, Wilasrusmee C, Leelahavarong P, Thakkinstian A, Teerawattananon Y.
    Cost-utility analysis of great saphenous vein ablation with radiofrequency, foam and surgery in the emerging health-care setting of Thailand.
    Phlebology. 2015 Sep 4. [Epub ahead of print].

  • Atasoy MM.
    Fill and aspirate foam sclerotherapy (FAFS): a new approach for sclerotherapy of large superficial varicosities concomitant to endovenous laser ablation of truncal vein.
    Clin Radiol. 2015 Jan;70(1):48-53.

  • de Franciscis S, Nobile C, Larosa E, Montemurro R, Serra R.
    Air contamination in the sclerosing foam for the treatment of varicose veins.
    Phlebology. 2014 Dec 15. [Epub ahead of print]

  • Lloret P, Redondo P, Cabrera J, Sierra A.
    Treatment of venous leg ulcers with ultrasound-guided foam sclerotherapy: Healing, long-term recurrence and quality of life evaluation.
    Wound Repair Regen. 2015 May-Jun;23(3):369-78.

  • Connor DE, Cooley-Andrade O, Goh WX, Ma DD, Parsi K.
    Detergent sclerosants are deactivated and consumed by circulating blood cells.
    Eur J Vasc Endovasc Surg. 2015 Apr;49(4):426-31.

  • Kurdal AT, Yildirim F, Ozbakkaloglu A, Iskesen I, Tetik O.
    Ultrasound-guided catheter-directed foam sclerotherapy for great saphenous vein.
    Minerva Chir. 2015 Feb;70(1):33-6.

  • Campos W Jr, Torres IO, da Silva ES, Casella IB, Puech-Leão P.
    A prospective randomized study comparing polidocanol foam sclerotherapy with surgical treatment of patients with primary chronic venous insufficiency and ulcer.
    Ann Vasc Surg. 2015 Aug;29(6):1128-35.

  • Friedmann DP, Liolios AM, Wu DC, Goldman MP, Eimpunth S.A
    Randomized, Double-Blind, Placebo-Controlled Study of the Effect of a High-Potency Topical Corticosteroid After Sclerotherapy for Reticular and Telangiectatic Veins of the Lower Extremities.
    Dermatol Surg. 2015 Oct;41(10):1158-63.

  • Augustin M, Debus ES, Bruning G, Faubel R, Lorhberg D, Goepel L, Herberger K, Blome C.
    Development and validation of a short version of the Freiburg life quality assessment for chronic venous disease (FLQA-VS-10).
    Wound Medicine 2015; 8:31-35.

  • Ali A, Wirth S, Treitl KM, Treitl M.
    Treatment of male varicoceles by transcatheter polidocanol foam sclerotherapy: evaluation of clinical success, complications, and patients' satisfaction with regard to alternative techniques.
    Eur Radiol. 2015 Oct;25(10):2889-97
2016

2016

  • Gillet JL; Desnos CH; Lausecker M; Daniel C; Guex JJ; Allaert FA:
    Sclerotherapy is a safe method of treatment of chronic venous disorders in older  patients: A prospective and comparative study of consecutive patients.
    Phlebology, Epub ahead of print 2016

  • Huang Y; Gloviczki P:
    Relationships between duplex findings and quality of life in long-term follow-up of patients treated for chronic venous disease.
    Phlebology 31, 1, 88-98, 2016

  • Kurnicki J; Osęka M; Tworus R; Gałązka Z:
    Ultrasound-guided foam sclerotherapy of great saphenous vein with 2% polidocanol - one-year follow-up results.
    Wideochir Inne Tech Maloinwazyjne, Epub ahead of print 2016

  • Pavei P; Ferrini M; Spreafico G; Nosadini A; Piccioli A; Giraldi E; Baccaglini U:
    Ultraschallgeführte Schaumsklerotherapie bei Rezidivvarikose der Stammvenen: Fünf-Jahres-Follow-up.
    Vasomed 28, 5, 234-237, 2016

  • Reich-Schupke S; Mendoza E; Dörler M; Stücker M:
    Frequency of refluxive tributaries of the junction region in the groin in patients with recurrent varicose veins of the thigh.
    Phlebologie 45, 3, 149-153, 2016

  • Sica M; Biasi G; Pozza M:
    Pushing the limits of ultrasound-guided sclerotherapy with foam.
    Phlébologie 69, 2, 23-27, 2016

  • Verma V; Mohil RS; Kumar S; Gupta A:
    Comparing ultrsound foam sclerotherapy with surgical treatment in patients of varicose veins.
    Int Surg J 3, 4, 2239-2245, 2016

  • Doganci S; Yildirim V; Erol G; Yesildal F; Karabacak K; Kadan M; Ozkan G; Ince ME; Ozgurtas T:
    Polidocanol (Lauromacrogol 400) has anti-angiogenic effects in vitro and in vivo.
    Eur Rev Med Pharmacol Sci 20, 7, 1384-1389, 2016

  • Cooley-Andrade O; Goh WX; Connor DE; Ma DD; Parsi K:
    Detergent Sclerosants Stimulate Leukocyte Apoptosis and Oncosis.
    Eur J Vasc Endovasc Surg 51, 6, 846-856, 2016

  • Deijen CL; Schreve MA; Bosma J; de Nie AJ; Leijdekkers VJ; van den Akker PJ; Vahl A:
    Clarivein mechanochemical ablation of the great and small saphenous vein. Early treatment outcomes of two hospitals.
    Phlebology 31, 3, 192-197, 2016
2017

2017

  • Bush R, Bush P.
    Evaluation of sodium tetradecyl sulfate and polidocanol as sclerosants for leg telangiectasia based on histological evaluation with clinical correlation.
    Phlebology. 2017; 32(7):496-500.

  • Recke AL, Frendel A, Kahle B.
    Operative und postoperative Risiken kombinierter Eingriffe mittels perkutaner Phlebektomie und Schaumsklerosierung.
    Phlebologie 2017 46 2: 75-80.

  • Murena-Schmidt RD.
    Ultraschallgesteuerte Schaumsklerosierung der Vena saphena parva Mehr als nur eine Therapiealternative?
    Phlebologie 2017 46 2: 60-62

  • Kahle B, Friedrichsen L, Recke AL.
    Schaumsklerosierung bei geriatrischen Patienten.
    Phlebologie 2017 46 4: 224-226.

  • Lal BK, Mallick R, Wright D.
    Improvement in patient-reported outcomes of varicose veins following treatment with polidocanol endovenous microfoam.
    Phlebology. 2017; 32(5):342-354.

  • Yin H, He H, Wang M, Li Z, Hu Z, Yao C, Wang J, Wang S, Chang G.
    Prospective Randomized Study of Ultrasound-Guided Foam Sclerotherapy Combined with Great Saphenous Vein High Ligation in the Treatment of Severe Lower Extremity Varicosis.
    Ann Vasc Surg. 2017; 39:256-263.

  • Tan L, Wong K, Connor D, Fakhim B, Behnia M, Parsi K.
    Generation of sclerosant foams by mechanical methods increases the foam temperature.
    Phlebology. 2017; 32(7):501-505.

  • Takai Y, Hiramoto K, Nishimura Y, Ooi K.
    Relationship between biochemical factors and skin symptoms in chronic venous disease.
    Arch Dermatol Res. 2017; 309(4):253-258.

  • Gao Z, Zhang Y, Li W, Shi C.
    Effectiveness and safety of polidocanol for the treatment of hemangiomas and vascular malformations: A meta-analysis.
    Dermatol Ther. 2018; 31(1).

  • Yamaki T, Sasaki Y, Hasegawa Y, Osada A, Konoeda H, Hamahata A, Nozaki M, Sakurai H.
    Percutaneous ultrasound-guided sclerotherapy with polidocanol microfoam for lymphatic malformations.
    J Vasc Surg Venous Lymphat Disord. 2017; 5(5):707-714.

Seite teilen

https://www.phlebology.de/aerzte/wissen/arbeitsgemeinschaften/ag-sklerotherapie/